BioInfra Life Science Inc. (XKON: 266470)
South Korea
· Delayed Price · Currency is KRW 207.00
-33.00 (-13.75%)
Nov 22, 2024, 9:00 AM KST
BioInfra Life Science Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|
Period Ending | Mar '20 Mar 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 |
| Net Income | -3,594 | -3,278 | -3,807 | -3,996 | -4,603 |
| Depreciation & Amortization | 376.3 | 347.07 | 273.1 | 178.4 | 127.89 |
| Loss (Gain) From Sale of Assets | - | - | 42.58 | 112.69 | 55.59 |
| Asset Writedown & Restructuring Costs | - | - | - | 816.23 | 1,175 |
| Loss (Gain) From Sale of Investments | -15.49 | -77.2 | -14.67 | - | - |
| Stock-Based Compensation | 25.08 | 39.04 | 132.29 | 206.53 | 149.96 |
| Provision & Write-off of Bad Debts | 61.88 | -45.17 | 91.39 | 4.95 | -17.51 |
| Other Operating Activities | 525.91 | 264.66 | 221.33 | -332.25 | -21.97 |
| Change in Accounts Receivable | 66.86 | 132.96 | -519.78 | -656.97 | -265.68 |
| Change in Inventory | - | - | - | - | 129.48 |
| Change in Other Net Operating Assets | -319.79 | -318.38 | -77.51 | 111.53 | -362.51 |
| Operating Cash Flow | -2,873 | -2,935 | -3,658 | -3,555 | -3,633 |
| Capital Expenditures | -81.61 | -53.61 | -453.58 | -52.49 | -127.33 |
| Sale of Property, Plant & Equipment | 0.9 | - | 12.27 | - | 60.73 |
| Sale (Purchase) of Intangibles | - | - | 2.83 | 120.91 | -300 |
| Investment in Securities | -7,162 | -7,047 | 564.27 | -806.43 | 8,496 |
| Other Investing Activities | 214.74 | 398.04 | 842.04 | 771.5 | -937.35 |
| Investing Cash Flow | -6,993 | -6,670 | 1,344 | 191.98 | 7,056 |
| Long-Term Debt Issued | - | 4,000 | 497.88 | - | - |
| Short-Term Debt Repaid | - | - | - | - | -290 |
| Long-Term Debt Repaid | - | -52.53 | - | - | - |
| Total Debt Repaid | -69.55 | -52.53 | - | - | -290 |
| Net Debt Issued (Repaid) | 3,930 | 3,947 | 497.88 | - | -290 |
| Issuance of Common Stock | 118.87 | 118.87 | 1,168 | 85.46 | 164.3 |
| Repurchase of Common Stock | -0.93 | -0.93 | - | - | - |
| Other Financing Activities | -0 | -0 | 170.33 | - | - |
| Financing Cash Flow | 10,048 | 10,065 | 1,836 | 85.46 | -125.7 |
| Foreign Exchange Rate Adjustments | 2.54 | -1.44 | 4.09 | -26.23 | -9.85 |
| Net Cash Flow | 184.57 | 458.15 | -473.72 | -3,303 | 3,287 |
| Free Cash Flow | -2,955 | -2,989 | -4,112 | -3,607 | -3,760 |
| Free Cash Flow Margin | -166.11% | -159.45% | -265.03% | -263.31% | -242.66% |
| Free Cash Flow Per Share | -218.93 | -221.65 | -299.20 | -278.95 | -294.93 |
| Cash Interest Paid | 6.88 | 5.32 | - | - | 0.83 |
| Cash Income Tax Paid | - | -5.77 | 3.69 | -23.72 | 19.4 |
| Levered Free Cash Flow | -1,498 | -1,430 | -1,670 | -2,210 | - |
| Unlevered Free Cash Flow | -1,314 | -1,302 | -1,653 | -2,172 | - |
| Change in Net Working Capital | -587.68 | -471.27 | -651.26 | 676.5 | - |
Source: S&P Capital IQ. Standard template. Financial Sources.